Pathologists and Research Team at Dana-Farber/Brigham and Women’s Use Next-Gen Sequencing to Create Faster, More Accurate Cancer Test
This advanced medical laboratory test looks for 95 genetic mutations associated with cancers of the blood and may provide pathologists with a new diagnostic tool
Seeking a faster time to answer when diagnosing patients with cancers of the blood, researchers and pathologists at the Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) in Boston have developed a unique clinical laboratory assay that involves multiple genes and just takes days to perform.
This high-tech genetic diagnostic test is called Rapid Heme Panel. It scans DNA in blood or bone marrow specimens. It uses powerful next-gen sequencing technology that searches for 95 genes that frequently mutate in blood cancers, according to a press release issued by DF/BWCC.
At Dana-Farber/Brigham and Women’s cancer center, this medical laboratory test is used in patients with leukemia, Myelodysplastic syndromes caused by poorly formed or dysfunctional blood cells, and myeloproliferative disorders that fill the bone marrow with abnormal blood cells. (more…)
